Abstract
Acute kidney injury is a complication of open-heart surgery that carries a poor prognosis. Studies have shown that postoperative renal function deterioration in cardiovascular surgery patients increases in-hospital mortality and adversely affects long-term survival. Identifying individuals at risk for developing AKI and aggressive early intervention is extremely important to optimize outcomes. This paper provides an overview of the etiology, prognostic markers, risk factors, and prevention of AKI and treatments that may favorably affect outcomes.

Introduction
The development of acute kidney injury (AKI) after cardiovascular surgery (CVS) has been well recognized in the past and is implicated as a contributing factor in the elevated mortality and poor outcomes of these patients. AKI following major CVS has a complex and multifactorial etiology. Despite advances in its management, AKI continues to contribute to the poor short- and long-term outcomes of CVS. The identification of high-risk individuals, development of protective maneuvers, and use of markers of early kidney injury are important in the early detection and proper treatment of this serious complication.

Definition of AKI after CVS
The definition of AKI after CVS differs in published studies; some describe it as a percent of increment from baseline creatinine, while others call it a doubling of the preoperative creatinine. As a rule, this syndrome is characterized by a deterioration of kidney function over a period of hours or days following surgery, with symptoms including oliguria (urine output less than 400 ml/day, which usually results in volume overload), paralleling elevations of serum blood urea nitrogen (BUN) and creatinine (Cr), and the development of serious electrolyte and acid-base disorders.

Recently, the Kidney Disease Improving Global Outcomes (KDIGO) developed a staging classification of AKI that includes three stages based on elevation of serum creatinine from baseline and urinary output (Figure 1). The hope is that this system will be universally adopted to enable future understanding of the incidence, outcomes, and effectiveness of therapeutic interventions for AKI.

The proper clinical differentiation between pre-renal, intrinsic-renal, and post-renal causes of AKI remains a useful approach to this problem (Table 1). Frequently the history (vomiting, diarrhea,
aggressive diuresis, exposure to nephrotoxin, cardiovascular collapse, complicated pelvic surgery, symptoms of prostatism) and physical examination (features of volume depletion, hypotension, bladder distention) provide important clues to help classify cases into pre-renal, intrinsic-renal, or post-renal categories. However, the history and physical examination are often inconclusive, and laboratory tests are necessary to better differentiate the problem.

Urinary tests need to be obtained before diuretics are given since, except for fractional excretion (Fe) uric acid and Fe urea, these tests would be equivocal due to diuretic-induced natriuresis and dissipation of medullary tonicity, thus falsely affecting fractional sodium excretion (Fena) and urine osmolality. Although Bun and serum Cr continue to be “the” markers of kidney function, their levels can be affected by several extra-renal factors. Moreover, their elevation is an indication that AKI had occurred earlier (Table 2).

Table 2. Extra-renal causes that affect creatinine and BUN levels.

| Creatinine Elevated | Low | BUN Elevated | Low |
|---------------------|-----|--------------|-----|
| Muscle Mass ↑       | ↓   | Muscle Mass  | Hypercatabolism | Liver Disease |
| Muscle Injury (rhabdomyolysis) |    | Volume Depletion | Starvation |
| Drugs: Cefoxitin   |    | Steroids    |   |
|        Cimetidine  |    | CHF         |   |
|        TMP-SMZ     |    | Hydroxyurea |   |
| Supplements: Creatine |    | Tissue Necrosis (gangrene) |   |
|                     |    | Intraproperitoneal Urine |   |
|                     |    | Extravasation |   |

Minor elevation of serum creatinine after CVS is a poor prognostic marker. Lately, the use of urinary neutrophil gelatinase-associated lipocalin (NGAL) has been shown to be an early predictor of severity, duration of AKI, length of hospitalization, dialysis requirement, and mortality. Another marker of rapid and early detection of AKI is the Kim-1 dipstick, which provides important clinical information. Serum cystatin C appears to be better than urinary cystatin C at predicting AKI and providing prognostic information. However, there are factors other than glomerular filtration rate (GFR) that can affect this marker, such as inflammation, age, gender, and race. Together, urine IL-18, urine NGAL, and plasma NGAL were shown to significantly improve risk prediction and poor outcomes among patients undergoing cardiac surgery. Likewise, preoperative proteinuria appears to be an accurate predictor of AKI among adults after coronary artery bypass surgery.

There have been several biomarkers of AKI identified according to the site of injury at the nephron (Figure 2). Hopefully in the future, a simple test simultaneously measuring some of these markers may become available for clinical use.

Despite advances in technology, a critical review of the urine sediment, preferably by the physician, continues to be an inexpensive, noninvasive, and dependable diagnostic tool (Figure 3).

Volume depletion (pre-renal) and obstruction (post-renal) can contribute to AKI if not recognized and properly corrected. However, AKI following CVS is mostly secondary to renal ischemia resulting from heart failure, cardiovascular collapse, interruption of renal circulation, vasopressors, and “post-pump syndrome” — with complement activation leading to mesangioproliferative changes that together result in decreased glomerular filtration. At times, AKI could result from intraoperative dye exposure or as a consequence of an atheroembolic renal insult, particularly following aortic aneurysm repair. Other contributing factors include pigment-induced tubular injury such as hemoglobinuria, a consequence of hemolysis and multiple transfusions, and myoglobinuria, which results from ischemic muscle injury (rhabdomyolysis). Of note is that both situations will show strongly positive occult blood in the urine dipstick without appreciable hematuria. Lactate
dehydrogenase levels and total creatine phosphokinase would differentiate hemoglobinuria from myoglobinuria. Alternatively, gel acrylic urine electrophoresis would establish a more accurate diagnosis. Advanced age, hyperbilirubinemia, sepsis, and the use of angiotensin converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), nonsteroidal anti-inflammatory drugs (NSAIDs), or radio-contrast dye immediately before surgery can predispose to AKI following CVS. However, the most predictable risk factor by far for AKI appears to be pre-existing CKD.

Pathogenesis of AKI after CVS

AKI develops under different clinical scenarios, and this complicates the understanding of the pathophysiology both clinically and experimentally. Age, race, gender, comorbid conditions, medication intake, type of surgery, duration of surgery, and certainly pre-existing CKD are all important variants to consider. The Cleveland Clinic has developed a score card to predict AKI after CVS (Table 3).  

Renal ischemia results in decreased GFR by a complex mechanism stemming from reduction in renal blood flow; this leads to vasoconstriction, which in turn leads to endothelial cell swelling that can be patchy and temporal. Other findings include thickening and fibrosis of the adventitia of interlobular arteries and afferent arterioles. Vasocostrictive humoral factors such as increased intrarenal renin activity, increased production of adenosine, thromboxanes, and endothelin have also been implicated in the genesis of AKI. Increased sensitivity to the adrenergic system could also play a role in the diminished GFR.

Disrupting the integrity of the ischemic tubules has been shown to result in back leak of the glomerular filtrate into the interstitium. The more severe the ischemic insult, the worse the back leak. This leads to interstitial edema that impairs arterial microcirculation due to external interstitial pressure buildup, resulting in diminished filtration, severe oliguria, and anuria. Tubular obstruction from desquamated proximal tubule microvilli and cellular debris (resulting from ischemic damage) mixed with

### Risk Score for Acute Renal Failure after Cardiac Surgery

| ARF Score | Points | Risk for Dialysis Dependent ARF | Risk |
|-----------|--------|--------------------------------|------|
| Risk Factor |        | Score                           |      |
| Female Gender | 1      | 0-2                             | 0.4% |
| LV Ejection Fraction <35% | 1      | 3-5                             | 1.8% |
| Preoperative use of IABP | 2      | 6-8                             | 9.5% |
| COPD | 1      | 9-13                            | 21.3% |
| Insulin-required diabetes | 1      | Based on review of 33,217 cases of open-heart surgery at Cleveland Clinic from 1993-2002. |
| Previous Cardiac Surgery | 1      |                                |      |
| Emergency Surgery | 2      |                                |      |
| Valve Surgery Only | 1      |                                |      |
| CABG + Valve Surgery | 2      |                                |      |
| Other Cardiac Surgery | 2      |                                |      |
| Preoperative Creatinine 1.2-2.1 mg/dL | 2      |                                |      |
| Preoperative Creatinine >2.1 mg/dL | 5      |                                |      |

Table 3. Cleveland Clinic risk score for predicting AKI.  

Figure 3 A and B. Critical review of urine sediment. 14

Urine Sediment with Sedi-Stain™ showing epithelial cellular inclusion cast.

Kidney biopsy showing tubular necrosis with epithelial tubular cell detachment entrapped by Tamm-Horsfall protein before being in the urine.
Tamm-Horsfall protein casts also contribute to oliguria (Figure 4).

Strategies to promote renal recovery remain limited; however, studies using growth factors are underway and may be promising for future use. Epidermal growth factor (EGF) is capable of stimulating proliferation of epithelial cells. In experimental models of ischemic AKI, EGF shortened recovery time. However, EGF has been implicated in the development of human cancers including renal cell carcinoma, thus limiting its use. Insulin-like growth factor 1 (IGF-1) initially was considered a good therapeutic choice to enhance renal recovery based on its beneficial effects in experimental models of AKI. However, human trials have failed to demonstrate a beneficial effect. Thyroxine had beneficial effects in ischemic and toxic animal experimental models of AKI, but they too have not been supported in human trials. Hepatocyte growth factor (HGF), initially identified as a mitogenic factor for hepatocytes, was subsequently found to have nonspecific cellular proliferative effects including oncogenic cells, thus limiting its use in clinical trials. Bone morphogenic protein 7 (BMP-7) has been shown to be essential for kidney, skeletal, and ocular development. Renal ischemia reduces BMP-7, and exogenous administration of BMP-7 in experimental renal ischemia attenuates the severity of the injury histologically and chemically. As such, BMP-7 remains a promising pharmacologic strategy once the mechanism for its beneficial effect is fully elucidated.

**Risk Factors for AKI after CVS**

In general, it is agreed that pre-existing CKD, advanced age, diabetes mellitus, congestive heart failure, generalized atherosclerosis, cardiovascular collapse, and dye exposure immediately followed by surgery are all risk factors for AKI after CVS and warrant the need for preoperative nephrology consultation. Studies have shown that race may affect mortality with AKI after CVS, indicating better survival in African American versus white patients. Female gender appears to have an increased incidence of AKI after open-heart surgery. Lower serum ferritin levels (<130 mg/dL) appear to be associated with AKI due to the inability to bind free iron (a potent oxidative stress inducer) generated during cardiopulmonary bypass-induced hemolysis.

**Prevention of Post-CVS AKI**

AKI is a complex process involving apoptosis and necrosis of injured tubular cells with simultaneous repair and proliferation of the surviving tubular cells. In addition to general maneuvers designed to optimize the patient’s overall condition, such as discontinuation of potentially detrimental drugs at least 48 hours prior to surgery (including ACE-Is, ARBs, NSAIDs, metformin, diuretics, when possible) and achieving normovolemia, there have been many different attempts to prevent AKI after CVS. Observational studies using calcium channel blockers such as nifedipine, diltiazem, and nicardipine showed beneficial effects, but their use never qualified as accepted standards of care. A meta-analysis of 16 randomized studies showed beneficial effects using Fenoldopam, which appears to reduce the need for dialysis and mortality in critically ill patients with or at risk of AKI. Mannitol and dopamine failed to protect against AKI during thoracic aortic cross-clamping. Likewise, dopamine and furosemide were shown to lack renoprotective effects during cardiac surgery. The use of atrial natriuretic peptide (ANP) in AKI also failed to show beneficial renoprotective effects. However, at times dopamine can help to initiate diuresis when a loop diuretic alone is insufficient. Although ACE-I/ARB therapy should be avoided in most cases, the use of intravenous enalaprilat has improved kidney performance in patients who have undergone coronary artery bypass complicated by left ventricular dysfunction. Intravenous pentoxifylline in elderly patients showed a prophylactic beneficial effect on postoperative organ function, but more studies are needed to assess its efficacy; moreover, this compound is not available in the United States. The use of automatic pulsatile intra-aortic balloon pumps during cardiopulmonary bypass has been associated with better kidney function. Off-pump coronary artery bypass may be associated with a lower incidence of postoperative AKI but did not affect the need for dialysis. In a randomized, single-blind, controlled pilot trial of 120 adult patients undergoing cardiopulmonary bypass, remote ischemic preconditioning resulted in a 27% absolute risk reduction of AKI.

**Treatment of AKI after CVS**

There are different degrees of AKI, but the term “kidney failure” implies the need for renal replacement therapy. There is no agreement in terms of timing for initiating dialysis, duration, and modality of conventional hemodialysis (HD) versus continuous venovenous hemodialysis (CVVHD). However, there are standards of care that mandate the initiation of dialysis in severe refractory acidemia (pH <7.2) or persistent intractable alkalemia.
hemodialysis

Keywords:

the other; ultimately, the proper modality of dialytic therapy becomes an
that one modality of dialytic therapy improves outcomes over
interleukin-6, tumor necrosis factor-alpha), there is no evidence
complicated by bleeding and sepsis. in general, the mortality of
combined cardiac, hepatic, pulmonary, and renal failure often
as cause of death when in reality these patients are dying from
multiple organ and system failure.4 7, 4 8

from 10% in those with uncomplicated aki to 80% in those with
aki varies according to the patient population studied, ranging
important. if aki develops, proper daily modification of
proactive early intervention to optimize outcomes is extremely
renal replacement therapy. identifying at-risk individuals and
medication dosing and avoidance of potentially nephrotoxic
balloon when indicated should help minimize the extent of aki.
using inotropic and vasopressor agents as well as intra-aortic
overall treatment. Finally, timely initiation of hd or Cvvhd to
be used depending on the clinical setting. early termination of
Cautious volume replacement or the use of loop diuretics can

Summary

AKI continues to complicate CVS and is an important
contributor of short- and long-term mortality. Elderly patients
(above age 65) with underlying Ckd preoperatively may never
regain kidney function following AKI and may require lifetime
renal replacement therapy. Identifying at-risk individuals and
proactive early intervention to optimize outcomes is extremely
important. If AKI develops, proper daily modification of
medication dosing and avoidance of potentially nephrotoxic
agents is mandatory. Likewise, restoration of hemodynamics
using inotrope and vasopressor agents as well as intra-aortic
balloon when indicated should help minimize the extent of AKI.
Cautious volume replacement or the use of loop diuretics can be
used depending on the clinical setting. Early termination of
ventilator support as well as sepsis prevention (i.e., removing
unnecessary lines, aggressive wound care) can favorably impact
the course of AKI. Proper nutrition to promote tissue repair and
to secure immunocompetence is also an important part of the
overall treatment. Finally, timely initiation of HD or CVVHD to
simultaneously correct fluid overload and metabolic disarray
should be initiated as the clinical setting dictates.

Conflict of Interest Disclosure: All authors have completed and submitted
the Methodist DeBakey Cardiovascular Journal Conflict of Interest Statement
and none were reported.

Funding/Sponsorship: The authors have no funding disclosures.

Keywords: acute kidney injury, AKI, cardiovascular surgery, KDIGO
staging classification, continuous venovenous hemodialysis, conventional
hemodialysis

References

1. Bhat JG, Gluck MC, Lowenstein J, Baldwin DS. Renal failure after open heart surgery. Ann Intern Med. 1976 Jun;84(6):677-82.

2. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al. Minimal changes of serum creatine
nine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004 Jun;15(6):1597-605.

3. Loef BG, Eperna AH, Smilde TD, Henning RH, Ebelts T, Navis G, et al. Immediate postoperative renal function deterioration in
cardiac surgical patients predicts in-hospital mortality and long-
term survival. J Am Soc Nephrol. 2005 Jan;16(1):195-200.

4. Parker RA, Himmlerfarb J, Tolkoff-Rubin N, Chandran P, Wingard RL, Hakim RM. Prognosis of patients with acute renal
failure requiring dialysis: results of a multicenter study. Am J Kidney Dis. 1998 Sep;32(3):432-43.

5. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, et al. Urine NGAL predicts severity of acute kidney injury after
cardiac surgery: a prospective study. Clin J Am Soc Nephrol. 2008 May;3(3):665-73.

6. McLroy DW, Wagener G, Lee HT. Neutrophil gelatinase-asso-
ciated lipocalin and acute kidney injury after cardiac surgery:
the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol. 2010 Feb;5(2):211-9.

7. Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT. Urinary neutrophil gelatinase-lipocalin and acute
kidney injury after cardiac surgery. Am J Kidney Dis. 2008 Sep;52(3):425-33.

8. Vaidya VS, Ford GM, Waikar SS, Wang Y, Clement MB, Ramirez V, et al. A rapid urine test for early detection of kidney injury. Kidney Int. 2008 Jul;76(1):108-14.

9. Zhang Z, Lu B, Sheng X, Jia N. Cystatin C in prediction of
acute kidney injury: a systemic review and meta-analysis. Am J Kidney Dis. 2011 Sep;58(3):356-65.

10. Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al. Factors other than glomerular filtration rate affect serum
creatinine concentrations. Kidney Int. 2009 Mar;75(6):652-60.

11. Parkih CR, Devarajan P, Zappitelli M, Sint K, Thiessen-Phil-
brook H, Li S, et al. Postoperative biomarkers predict acute
kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011 Sep;22(9):1737-47.

12. Huang TM, Wu VC, Young GH, Lin YF, Shiao CC, Wu PC, et al. Pre-operative proteinuria predicts adverse renal outcomes
after coronary artery bypass grafting. J Am Soc Nephrol. 2011 Jan;22(1):156-63.

13. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterie F.
Next-generation biomarkers for detecting kidney toxicity. Nat
Biotechnol. 2010 May;28(5):436-40.

14. Perazella MA, Coca SG. Traditional urinary biomarkers in the
assessment of hospital-acquired AKI. Clin J Am Soc Nephrol. 2012 Jan;7(1):167-74.

15. Thakar CV, Arrigain S, Worley S, Yared JP, Paganini EP. A Cli-
nical Score to Predict Acute Renal Failure after Cardiac Surgery. J Am Soc Nephrol. 2005 Jan;16(1):162-8.

16. Arteaga CL. The epidermal growth factor receptor: from mutant
oncogene in nonhuman cancers to therapeutic target in human
neoplasia. J Clin Oncol. 2001 Sep 15;19(18 Suppl);32S-40S.

17. Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albert-
son T, et al. Multicenter clinical trial of recombinant human
insulin-like growth factor 1 in patients with acute renal failure.
Kidney Int. 1999 Jun;55(6):2423-32.
18. Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP. A trial of thyroxine in acute renal failure. Kidney Int. 2000 Jan;57(1):293-8.

19. Vargas G, Hoeflich A, Jehle P. Hepatocyte growth factor in renal failure: promise and reality. Kidney Int. 2000 Apr;57(4):1426-26.

20. Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, et al. Osteogenic protein-1 (bone morphogenic protein-7) reduces severity of kidney injury after ischemic acute renal failure in rat. J Clin Invest. 1998 Jul 1;102(1):202-14.

21. Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabrò MG, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis. 2007 Jan;49(1):56-68.

22. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR, et al. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 Jun;53(6):961-73.

23. LeMaire S, Miller CC 3rd, Conklin LD, Schmitting ZC, Kóksoy C, Coselli JS. A new predictive model for adverse outcomes after elective thoracoabdominal aortic aneurysm repair. Ann Thorac Surg. 2001 Apr;71(4):1233-8.

24. Anderson RJ, O’Brien M, MaWhinnie N, VillaNueva CB, Moritz TE, Sethi GK, et al. Renal failure predisposes patients to adverse outcomes after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int. 1999 Mar;55(3):1057-62.

25. Waikar SS, Curhan GC, Ayanian JZ, Chertow GM. Race and mortality after acute renal failure. J Am Soc Nephrol. 2007 Oct;18(10):2740-48.

26. Thakar CV, Liangos O, Yared JP, Nelson D, Piedmonte MR, Hariharchar S, et al. ARF after open heart surgery: influence of gender and race. Am J Kidney Dis. 2003 Apr;41(4):742-51.

27. Davis CL, Kausz AT, Zager RA, Kharasch ED, Cochran RP. Acute renal failure after cardiopulmonary bypass is related to decreased serum ferritin levels. J Am Soc Nephrol. 1999 Nov;10(11):2396-402.

28. Antonucci F, Calo L, Rizzolo M, Cantaro S, Bertolissi M, Traghaglini, et al. Nifedipine can preserve renal function in patients undergoing aortic surgery with infrarenal crossclamping. Nephron. 1999;74(4):668-73.

29. Bergman AS, Odar-Cederlof, Westman L. Renal and hemodynamic effects of diltiazem after elective major vascular surgery—a potential renoprotective agent? Ren Fail. 1995 Mar;17(2):155-63.

30. Colson P, Ribstein J, Séguin JR, Marty-Ane C, Roguefeuil B. Mechanisms of renal hemodynamic impairment during infrarenal aortic cross-clamping. Anesth Analg. 1992 Jul;75(1):18-23.

31. Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 2005 Jul;46(1):26-34.

32. Pass LJ, Eberhart RC, Brown JC, Rohn GN, Estrera AS. The effect of mannitol and dopamine on the renal response to thoracic aortic cross-clamping. J Thorac Cardiovasc Surg. 1998 Apr;95(4):608-12.

33. Lassnigg A, Donner E, Grubhofer G, Prestel E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol. 2000 Jan;11(1):97-104.

34. Rahaman SN, Kim GE, Mathen AS, Goldberg CA, Allgren RW, Schrier RW, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int. 1994 Jun;45(6):1731-8.

35. Lauschke A, Teichgräber UK, Frei U, Eckardt KU. ‘Low dose’ dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int. 2006 May;69(5):1669-74.

36. Wagner F, Yeter R, Bisson S, Sinlavsht H, Hetzer R. Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction. Crit Care Med. 2003 May;31(5):1421-8.

37. Boldt J, Brosch C, Piper SN, Suttner S, Lehmann A, Weling C. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med. 2001 May;29(5):952-8.

38. Onorati F, Presta P, Fuiano C, Mastroroberto P, Corni N, Pezzo F, et al. A randomized trial of pulsatile perfusion using an intra-aortic balloon pump versus nonpulsatile perfusion on short-term changes in kidney function during cardiopulmonary bypass during myocardial reperfusion. Am J Kidney Dis. 2007 Aug;50(2):229-38.

39. Nigwekar SU, Kandula P, Hix JK, Thakar CV. Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized and observational studies. Am J Kidney Dis. 2009 Sep;54(3):414-23.

40. Seabra VF, Alobaidi S, Balk EM, Poon AH, Jaber BL. Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2010 Oct;5(10):1734-44.

41. Zimmerman RF, Ezeyounu PU, Kane JC, Cleland CD, Kempapanjappa TJ, Lucas FL, et al. Ischemic preconditioning at a remote site prevents acute kidney injury in patients following cardiac surgery. Kidney Int. 2011 Oct;80(8):861-7.

42. Gibney N, Hoste E, Burdeman EA, Bunchman T, Kher V, Viswanathan R, et al. Timing of initiation and discontinuation of renal replacement therapy in AKI: unanswered key questions. Clin J Am Soc Nephrol. 2008 May;3(3):876-80.

43. Bouchard J, Soroko SB, Chertow GM, Himelfarb J, Ikizler TA, Paganini EP, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009 Aug;76(4):422-7.

44. Davenport A, Bouman C, Kirpalani A, Skippen P, Tolwani A, Mehta RL, et al. Delivery of renal replacement therapy in acute kidney injury: what are the key issues? Clin J Am Soc Nephrol. 2008 May;3(3):869-75.

45. DuBose TD Jr, Warnock DG, Mehta RL, Bonventre JV, Hammerman MR, Molitoris BA, et al. Acute renal failure in the 21st century: recommendation for management and outcome assessment. Am J Kidney Dis. 1997 May;29(5):793-9.

46. Bartlett RH. Continuous renal replacement therapy in multiple organ failure. Am J Kidney Dis. 1996 Nov;28(5 Suppl 3):S97-99.

47. Cosentino F, Chaff C, Piedmonte M. Risk factors influencing survival in ICU acute renal failure. Nephrol Dial Transplant. 2004;19:471-82.

48. Liao F, Junco E, Pascual J, Madero R, Verde E. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. Kidney Int Suppl. 1998 May;66:S16-24.